trending Market Intelligence /marketintelligence/en/news-insights/trending/lgc9mVvdCj5t6vnsgoyrCg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Australian drug development company Phylogica rebrands to PYC Therapeutics

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Australian drug development company Phylogica rebrands to PYC Therapeutics

Phylogica Ltd. changed its name to PYC Therapeutics Ltd. to reflect the company's shifted focus from drug discovery to drug development.

The name change will come into effect after the company gets shareholder approval at its annual general meeting scheduled for later in the year.

The Perth, Australia-based company has registered the new trading name with the Australian Securities and Investments Commission. It has also submitted a trademark application to IP Australia regarding the new name.

The rebranding is in line with the latest changes in the company's executive board and scientific board.

Phylogica is developing a pipeline of therapies for blinding eye diseases using its proprietary technology.